论文部分内容阅读
为探讨Ｎ－ｒａｓ基因突变在骨髓增生异常综合征（ＭＤＳ）病变过程中的意义，采用多聚酶链反应－单链构象多态（ＰＣＲ－ＳＳＣＰ）分析法检测２０例ＭＤＳ患者Ｎ－ｒａｓ癌基因，其中５例出现Ｎ－ｒａｓ基因突变，占２５％，其中３例随访半年内转变为急性髓细胞白血病（ＡＭＬ），且对化疗不敏感。提示Ｎ－ｒａｓ基因突变可促进ＭＤＳ恶性克隆过度增生。初步表明Ｎ－ｒａｓ基因突变的检测可作为一种分子生物学标志，用于监测ＭＤＳ向ＡＭＬ转化
To investigate the significance of N-ras gene mutation in the pathogenesis of myelodysplastic syndrome (MDS), we used polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assay to detect N-ras oncogene in 20 patients with MDS. Among them, 5 cases showed N-ras gene mutation, accounting for 25%, of which 3 cases were converted to acute myeloid leukemia (AML) within six months of follow-up and were insensitive to chemotherapy. It suggests that N-ras gene mutation can promote the hyperplasia of MDS malignant clones. It has been initially shown that detection of N-ras mutations can be used as a molecular biomarker to monitor the conversion of MDS to AML.